DAE HWA PHARM Q1 2026 Report Overview
대화제약
067080
Signal Score
Historical Avg Return (5d)
-0.18%
Data Coverage
100%n=3385
Risk-adjusted indicator based on 3385 historical DART filings. For informational purposes only — not investment advice.
Financial Impact
NEUTRAL
Key Numbers
- • Total Revenue (Q1 2026): 37,032,014 KRW
- • Pharmaceutical Manufacturing & Sales Revenue (Q1 2026): 27,832,078 KRW
- • Liporaxel Oral Paclitaxel License-out Contract Value: 28.3B KRW + Running Royalty
- • Liporaxel Received NMPA Approval (China) for Gastric Cancer: Sep 2024
- • Liporaxel Received MFDS Approval (Korea) for Breast Cancer: May 13, 2026
AI Analysis Summary
DAE HWA PHARM's Q1 2026 report shows total revenue of 37,032,014 KRW, with pharmaceutical manufacturing and sales contributing 27,832,078 KRW. The company's key drug, Liporaxel, received NMPA approval in China for gastric cancer in September 2024 and MFDS approval in Korea for breast cancer on May 13, 2026. The license-out contract for Liporaxel in China, Taiwan, Hong Kong, and Thailand is valued at 28.3B KRW plus running royalties, with 16.3B KRW already received. While the report details operational aspects and R&D progress, specific quarterly profit figures are not provided in the excerpt, limiting a full financial impact assessment. The positive regulatory approvals for Liporaxel are a long-term growth driver, but the immediate financial impact is not quantifiable from the provided data.
How This Event Is Evaluated
Earnings Evaluation
Earnings events are evaluated by comparing profitability, growth, margin direction, and one-off factors against market expectations.
AI is used to interpret disclosures and extract structured data.
Signal scores are generated using event-specific methodologies and quantitative models.
- Revenue and profit growth
- Operating margin direction
- Net income quality
- One-off gains or losses
Track Korean Market Signals — Free
Sign up free to access live disclosures, AI analysis, and event filters.
Public Beta · No credit card required
This content is for informational purposes only and does not constitute investment advice. Past signal patterns do not guarantee future results. All data is sourced from public DART filings.